Long-term Folow-up of Indicators of Bone Metabolismin Female Patients with Osteoporosis Treated with Calcium and Collagen Peptides
M. Adam; P. Špaček; H. Hulejová
Revmatologický ústav, Praha
Čes. Revmatol., , 2002, No. 3, p. 131-137.
In 120 patients with postmenopausal osteoporosis (PMOP) with a bone mass density (BMD) lowerthan 80 %, indicators of bone metabolism were followed up – urinary pyridinoline (UPD) anddeoxypyridinoline (USPD), serum bone alkaline phosphatase (OAP) and serum osteocalcin (OC).The patients were divided by random sampling into two groups: one group was given calciumgluconate (CG) (500 mg/day) and the second one collagen peptide (CP) (10 g/day), both by the oralroute. The patients were followed up by clinical and laboratory methods every 6 months. Indicatorsof bone metabolismwere evaluated at the beginning and at the end of the three-year period. Duringthese three years, six patients who took CP and 22 patients who took CG dropped out. In patientswho took CP after three years reduced excretion ofUPDwas observed at the borderline of statisticalsignificance (from 56.19 to 41.88 nmol/mmol creatinine). The reduction of UPD excretion wasrecorded in particular in „fast losers“ (UPD > 80 nmol/mmol creatinine). Conversely, CP administrationhad an impact on a rise of OAP from 15.56 to 21.65 U/L (significant at the 1% level). Osteoblasticactivity measured by OAP was stimulated in particular in „slow losers“ (from 15.14 to 20.14 U/L).The values in the group treated with CG did not reach statistical signifikance.
postmenopausal osteoporosis, urinary pyridinoline, urinary deoxypyridinoline,serum osteocalcin, serum bone alkaline phosphatase, collagen peptides
Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP
Dermatology & STDs